In addition, and for the rest of the proteins studied, relationships with other clinical features of RA-ILD+ patients were found, observing associations of treatment and antibody status with levels of MMP-2 and TIMP-1, respectively. The gene discussed is MMP2; the disease is rheumatoid arthritis.